Portuguese Consensus on Acute Porphyrias: Diagnosis, Treatment, Monitoring and Patient Referral

• Autor(a) principal: Brito Avô, Luís
• Data de Publicação: 2023
• Outros Autores: Pereira, Luísa, Oliveira, Anabela, Ferreira, Filipa, Filipe, Paulo, Coelho Rodrigues, Inês, Couto, Eduarda, Ferreira, Fátima, Airosa Pardal, André, Morgado, Pedro, Moreira, Sónia
• Tipo de documento: Artigo
• Idioma: eng; por
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/20323
• topic: Consensus; Porphyria, Acute Intermittent/diagnosis; Porphyria, Acute Intermittent/therapy; Porphyrias/diagnosis; Porphyrias/therapy; Portugal; Referral and Consultation; Consenso; Encaminhamento e Consulta; Porfirias/diagnóstico; Porfirias/tratamento; Porfiria Aguda Intermitente/diagnóstico; Porfiria Aguda Intermitente/tratamento; Portugal

Acute porphyrias are a group of rare genetic metabolic disorders, caused by a defect in one of the enzymes involved in the heme biosynthesis, which results in an abnormally high accumulation of toxic intermediates. Acute porphyrias are characterized by potentially life-threatening attacks and, for some patients, by chronic manifestations that negatively impact daily functioning and quality of life. Clinical manifestations include a nonspecific set of gastrointestinal, neuropsychiatric, and/or cutaneous symptoms. Effective diagnostic methods are widely available, but due to their clinical heterogeneity and non-specificity, many years often elapse from symptom onset to diagnosis of acute porphyrias, delaying the treatment and increasing morbidity. Therefore, increased awareness of acute porphyrias among healthcare professionals is paramount to reducing disease burden. Treatment of acute porphyrias is centered on eliminating the potential precipitants, symptomatic treatment, and suppressing the hepatic heme pathway, through the administration of hemin or givosiran. Moreover, properly monitoring patients with acute porphyrias and their relatives is fundamental to preventing acute attacks, hospitalization, and long-term complications. Considering this, a multidisciplinary panel elaborated a consensus paper, aiming to provide guidance for an efficient and timely diagnosis of acute porphyrias, and evidence-based recommendations for treating and monitoring patients and their families in Portugal. To this end, all authors exhaustively reviewed and discussed the current scientific evidence on acute porphyrias available in the literature, between November 2022 and May 2023.